Search

Purpose: The study aims to provide a comprehensive overview of the various malignant and benign parotid tumours and evaluate the predictive factors for intraoperative nerve involvement leading to facial palsy (FP). Methods: It is a single-centre retrospective analysis for reviewing the involvement of facial nerve in post- parotidectomy patients. The clinical database from January 2012 to December 2020 was included in the study with a follow-up period of a minimum of 2 years. To maintain homogeneity, all squamous cell carcinomas of level 2 nodes involving parotid or residual/recurrent disease of the oral cavity requiring parotid dissection were excluded. Results: A total of 248 patients (171 benign; 77 malignant) were evaluated with a mean age of 46.48 ± 10.76 years. The presence of malignancy increases the risk of FP (p = 0.027). 37 (14.92%) patients with FP were detected which included 34 with partial [32.35% in malignant; 62.16% in recurrent pleomorphic adenoma (RPA)] and 3 with total paralysis (66.67% in malignant; 33.33% in RPA). The recurrence of pleomorphic adenoma increases FP. While old age, larger size, hard fixed swelling with masseteric space (MS) infiltration appeared as risk factors for FP in malignant tumours (p = 0.047; p = 0.004; p < 0.00001 respectively). Conclusion: Tumour size, malignancy, hard fixed mass, masseteric space infiltration, recurrence, and age > 45yrs have been statistically significant predictive factors for intraoperative facial nerve involvement leading to FP. The study also revealed that FP occurred more commonly when there was concurrent involvement of both superficial and deep lobes but was not statistically significant. [ABSTRACT FROM AUTHOR]

Plexiform Fibrohistiocytic Tumour (PFHT) is an intermediate malignant tumour of soft tissue. It is a rarely metastasising dermal subcutaneous neoplasm. It affects children and young adults. The age range of presentation is from birth to age 77 years. The tumour is most commonly located on the upper extremities, whereas the involvement of the frontal region is rare. The differential diagnosis includes benign fibrous histiocytoma, fibromatosis, giant cell tumour and neurofibroma. Plexiform fibrohistiocytic tumour is a slow-growing mass and which is considered a low grade malignant tumour. Treatment is simple excision. It can exhibit aggressive behaviour and rate of local recurrence is 12-38%. A 45-year-old female was presented with a solid mass on the frontal region of the head which was diagnosed as a plexiform fibrohistiocytic tumour with underlying frontal bone invasion on histopathological examination of an excised mass in the Pathology Department. Plexiform Fibrohistiocytic Tumour (PFHT) is a mesenchymal neoplasm that shows a multinodular growth pattern and which is composed of fibroblasts, histiocyte-like cells and multinucleated osteoclast like giant cells. Clinically, it is usually a slow-growing mass with frequent local recurrence and rare regional lymphatic and systemic metastasis. [ABSTRACT FROM AUTHOR]